Carcinogenic human papillomavirus infection

…, S De Sanjosé, C Fakhry, BJ Monk… - Nature reviews Disease …, 2016 - nature.com
Infections with human papillomavirus (HPV) are common and transmitted by direct contact.
Although the great majority of infections resolve within 2 years, 13 phylogenetically related …

Latest research and treatment of advanced-stage epithelial ovarian cancer

RL Coleman, BJ Monk, AK Sood… - Nature reviews Clinical …, 2013 - nature.com
The natural history of ovarian cancer continues to be characterized by late-stage
presentation, metastatic bulky disease burden and stagnant mortality statistics, despite …

Adhesions after extensive gynecologic surgery: clinical significance, etiology, and prevention

BJ Monk, ML Berman, FJ Montz - American journal of obstetrics and …, 1994 - Elsevier
Postoperative adhesions occur in 60% to 90% of patients undergoing major gynecologic
surgery and represent one of the most common causes of intestinal obstruction in the …

[HTML][HTML] Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer

MR Mirza, BJ Monk, J Herrstedt, AM Oza… - … England Journal of …, 2016 - Mass Medical Soc
Background Niraparib is an oral poly (adenosine diphosphate [ADP]–ribose) polymerase
(PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We …

Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage …

…, PY Liu, RJ Barrett, RJ Stock, BJ Monk… - Obstetrical & …, 2000 - journals.lww.com
This study investigated the addition of cisplatin-based chemotherapy to standard
postoperative radiation therapy in the treatment of women at high risk of recurrence after …

[HTML][HTML] Incorporation of bevacizumab in the primary treatment of ovarian cancer

…, MA Bookman, GF Fleming, BJ Monk… - … England Journal of …, 2011 - Mass Medical Soc
Background Vascular endothelial growth factor is a key promoter of angiogenesis and
disease progression in epithelial ovarian cancer. Bevacizumab, a humanized anti–vascular …

[HTML][HTML] Pembrolizumab for persistent, recurrent, or metastatic cervical cancer

…, S Toker, K Li, SM Keefe, BJ Monk - … England Journal of …, 2021 - Mass Medical Soc
Background Pembrolizumab has efficacy in programmed death ligand 1 (PD-L1)–positive
metastatic or unresectable cervical cancer that has progressed during chemotherapy. We …

Dostarlimab for primary advanced or recurrent endometrial cancer

…, MS Shahin, SE Gill, BJ Monk… - … England Journal of …, 2023 - Mass Medical Soc
Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell
death 1 receptor. The combination of chemotherapy and immunotherapy may have …

[HTML][HTML] Niraparib in patients with newly diagnosed advanced ovarian cancer

…, IA Malinowska, Y Li, D Gupta, BJ Monk - … England Journal of …, 2019 - Mass Medical Soc
Background Niraparib, an inhibitor of poly (adenosine diphosphate [ADP]–ribose)
polymerase (PARP), has been associated with significantly increased progression-free …

[HTML][HTML] Improved survival with bevacizumab in advanced cervical cancer

…, MM Leitao, HE Michael, BJ Monk - … England Journal of …, 2014 - Mass Medical Soc
Background Vascular endothelial growth factor (VEGF) promotes angiogenesis, a mediator
of disease progression in cervical cancer. Bevacizumab, a humanized anti-VEGF …